Understanding Catalysts in Biotech Trading

Hi. I'm John Galliano, senior director of BioPharm Catalyst. Hello. I'm Chef, known as Chef Station, a twenty year vet in trading biotech stocks. And this is Biotech Bulls and Breakthroughs. Biopharm Catalyst is not a registered investment advisory firm, and the views on this podcast are not intended to be financial advice. Guests on this podcast may hold the stocks discussed in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions. If you find the information on this podcast useful and would like more catalyst information, Biopharm Catalyst is your premier resource for catalyst data for over 1,000 publicly traded biotech companies. We track clinical trial based catalysts, everything from IND filings to drug data releases for phase one, two, and three trials to regulatory decisions. Our catalyst calendars are updated as soon as the press release comes out so you can be sure you have the most timely and accurate information to inform your biotech trading. All of our plans come with a seven day free trial, and we frequently run discounts on our platform. So check out www.biopharmcatalyst.com to get started today. Sorry. I forgot to mention that today is Tuesday, 10/28/2025. Good morning, good afternoon, good evening, depending on when you're, listening in and where where you're listening in from. Welcome once again to another episode of biotech bulls and breakthroughs. Again, we're always excited to have, chef on the line with us, for another episode this month to talk about what's been going on in the markets and what his thoughts are on, some of the upcoming catalysts as we approach year end. And I know we're chef, we were just talking, we were just talking before about how this is you know, it's kinda crazy that we're already October. We've got about two months left in the year, and just, you know, how time really flies. And it's certainly been a been an exciting year and exciting couple months in biotech and, you know, think that that's gonna those tailwinds are hopefully gonna continue into, 2026 as we were kinda just discussing before hopping on. Absolutely. And, you know, the interesting thing with those is that, you know, we've seen historically slow months, you know, really, do well. Like, the third you know, second quarter did well. The third quarter did well. And as we're heading into November and and seeing some of the tailwinds of these conferences, AACR is gonna be happening here over the next week. And then you've got, you know, into December, you've got ASH and you've got, you know, the San Antonio Breast Cancer Conference. So we we're we're shaping up to be a a really good end of the year run for biotechs. And and, clearly, this has has been one of the better years, I think that that I've had trading, and I've really enjoyed. Even with …